Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02340169 · ClinicalTrials.gov registry record · Phase 4
Adrenal Suppression and Pharmacokinetics of Topicort® Spray, 0.25% in Pediatric Patients With Plaque Psoriasis
A Phase 4 study, sponsored by Sun Pharmaceutical Industries.
- Completed
- Registry status
- Phase 4
- Development phase
- 129
- Enrollment target
NCT02340169 is a Phase 4 study that has completed, run by Sun Pharmaceutical Industries. The registered enrollment target is 129 participants.
The verdict
NCT02340169, a Phase 4 study, has completed, sponsored by Sun Pharmaceutical Industries.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 129 participants
- Enrollment target
Study Summary
The objective of this study is to evaluate the potential of Topicort® (desoximetasone) Topical Spray, 0.25% to suppress hypothalmic pituitary adrenal axis function. The secondary objectives are to evaluate the efficacy parameters, pharmacokinetics and adverse event profile.
Interventions
- DRUG Topicort® (desoximetasone) Topical Spray, 0.25%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 129 participants |
| Start Date | 2015-01-23 |
| Est. Completion | 2021-11-22 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02340169
The ClinicalTrials.gov registry entry for NCT02340169 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 129 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sun Pharmaceutical Industries, which has 48 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Topicort® (desoximetasone) Topical Spray, 0.25% is the first listed.
NCT02340169 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02340169 about?
NCT02340169 is a clinical study titled "Adrenal Suppression and Pharmacokinetics of Topicort® Spray, 0.25% in Pediatric Patients With Plaque Psoriasis". The objective of this study is to evaluate the potential of Topicort® (desoximetasone) Topical Spray, 0.25% to suppress hypothalmic pituitary adrenal axis function. The secondary objectives are to evaluate the efficacy parameters, pharmacokinetics and adverse event profile.
What is the current status of trial NCT02340169?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 129 participants. The study started on 2015-01-23. Estimated completion is 2021-11-22.
What interventions are being tested in trial NCT02340169?
The interventions under investigation include: Topicort® (desoximetasone) Topical Spray, 0.25% (DRUG).
Who is sponsoring clinical trial NCT02340169?
This trial is sponsored by Sun Pharmaceutical Industries, which has 48 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.